News related to Bexxar (Tositumomab / Iodine I 131 Tositumomab) and/or conditions it is approved for
Co-Founder Of Microsoft Diagnosed With Non-Hodgkin's Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.17]
Paul Allen who co-founded the computer giant Microsoft with Bill Gates in the 1970s has been diagnosed with Non-Hodgkin's Lymphoma, 25 years after surviving Hodgkin's lymphoma. The news was announced in a memo to the staff of Allen's company Vulcan, by CEO Jody Allen, who is also Paul Allen's sister. A copy of the memo was also sent to the media.
FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma
Source: Blood / Hematology News From Medical News Today [2009.11.12]
The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin) is injectable and is marketed by Gloucester Pharmaceuticals Inc of Cambridge, Massachusetts. Every year, about 1,500 Americans are newly diagnosed with CTCL, a type of non-Hodgkin's lymphoma.
Istodax Approved for Cutaneous T-Cell Lymphoma
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2009.11.09]
Title: Istodax Approved for Cutaneous T-Cell Lymphoma
Category: Health News
Created: 11/6/2009 4:10:00 PM
Last Editorial Review: 11/9/2009
FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma
Source: Blood / Hematology News From Medical News Today [2009.11.06]
Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response.
Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer
Source: Bones / Orthopaedics News From Medical News Today [2009.11.06]
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice.
Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA Induced Durable Responses In Relapsed Indolent Non-Hodgkin's Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.06]
Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.
New Data On Bendamustine Offers Hope To Non-Hodgkin's Lymphoma Patients Resistant To Standard Therapy
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.06]
New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin's lymphoma (iNHL), responded to treatment with Bendamustine following a single-arm, multicentre study. Significantly, all patients participating in the study had become resistant or were unresponsive to rituximab (the standard treatment for the disease) when used either as a single agent or in combination with other therapies. Professor Brad S.
FDA Okays New Treatment for T-Cell Lymphoma
Source: MedPage Today Product Alert [2009.11.06]
WASHINGTON (MedPage Today) -- The FDA has approved romidepsin (Istodax) for patients with cutaneous T-cell lymphoma who have received at least one prior systemic therapy.
Istodax Approved for Cutaneous T-Cell Lymphoma (HealthDay)
Source: Y! Health Lymphoma News [2009.11.06]
HealthDay - FRIDAY, Nov. 6 (HealthDay News) -- The Gloucester Pharmaceuticals
drug Istodax (romidepsin) has been approved by the U.S. Food and Drug
Administration to treat cutaneous T-cell lymphoma (CTCL) in people who
have tried at least one prior systemic therapy, the drug's manufacturer
said in a news release.
Immune Therapy Can Protect Against Or Treat Later Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.03]
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.
Immunotherapy Demonstrates Long-Term Success In Treating Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.31]
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research Initiative Grants
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.30]
The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.
Folotyn Approved for Aggressive Type of Non-Hodgkin's Lymphoma
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2009.09.28]
Title: Folotyn Approved for Aggressive Type of Non-Hodgkin's Lymphoma
Category: Health News
Created: 9/25/2009 12:10:00 PM
Last Editorial Review: 9/28/2009
Non-Hodgkins Lymphomas
Source: MedicineNet Biological Therapy Specialty [2009.08.14]
Title: Non-Hodgkins Lymphomas
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 8/14/2009
Immune-Based Lymphoma Treatment Shows Promise
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2009.06.01]
Title: Immune-Based Lymphoma Treatment Shows Promise
Category: Health News
Created: 6/1/2009 7:00:00 AM
Last Editorial Review: 6/1/2009
Statin Use Doesn't Inhibit Lymphoma Drug Therapy
Source: MedicineNet Hodgkins Disease Specialty [2008.12.10]
Title: Statin Use Doesn't Inhibit Lymphoma Drug Therapy
Category: Health News
Created: 12/10/2008 2:00:00 AM
Last Editorial Review: 12/10/2008
Breakthrough test clearly distinguishes Burkitt lymphoma from DLBCL
Source: The Doctors Lounge - Oncology
A gene expression signature clearly distinguishes Burkitt lymphoma from DLBCL, a critical distinction in diagnosis.
Seattle Genetics Initiates Phase I Clinical Trial Of Antibody-Drug Conjugate SGN-75
Source: Urology / Nephrology News From Medical News Today [2009.11.18]
Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company's proprietary technology.
|
